Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
Expands robotics to 20+ specialities
Proposed combination enhances Pfizer’s position as a leading company in oncology
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Time to combine innovation, access and technology to deliver positive patient outcomes
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Thiamine Hydrochloride Injection is effective in the treatment of vitamin B1 deficiency (beriberi)
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
Subscribe To Our Newsletter & Stay Updated
